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Abstract. Stockpiling of pre-pandemic inﬂuenza vaccines guarantees immediate vaccine availability to
counteract an emerging pandemic. Generally, inﬂuenza vaccines need to be stored and handled
refrigerated to prevent thermal degradation of the antigenic component. Requirement of a cold-chain,
however, complicates stockpiling and the logistics of vaccine distribution. We, therefore, investigated the
effect of elevated storage temperatures on the immunogenicity of a pre-pandemic inﬂuenza A H5N1
whole inactivated virus vaccine. Either suspended in liquid or kept as a freeze-dried powder, vaccines
could be stored for 1 year at ambient temperature (20°C) with minimal loss of immunogenicity in mice.
Elevation of the storage temperature to 40°C, however, resulted in a signiﬁcant loss of immunogenic
potency within 3 months if vaccines were stored in liquid suspension. In sharp contrast, freeze-dried
powder formulations were stable at 40°C for at least 3 months. The presence of inulin or trehalose sugar
excipients during freeze-drying of the vaccine proved to be critical to maintain its immunogenic potency
during storage, and to preserve the characteristic Th1-type response to whole inactivated virus vaccine.
These results indicate that whole inactivated virus vaccines may be stored and handled at room
temperature in moderate climate zones for over a year with minimal decline and, if converted to dry-
powder, even in hot climate zones for at least 3 months. The increased stability of dry-powder vaccine at
40°C may also point to an extended shelf-life when stored at 4°C. Use of the more stable dry-powder
formulation could simplify stockpiling and thereby facilitating successful pandemic intervention.
KEY WORDS: freeze-drying; inulin; pandemic inﬂuenza; vaccine stockpiling; whole inactivated
inﬂuenza vaccine (H5N1).
INTRODUCTION
Animal inﬂuenza A viruses that cross the species barrier
to humans pose a potential pandemic threat (1). Generally,
these virus subtypes are antigenically different from the
circulating human viruses and thus may spread rapidly in
the immunologically naïve population, if human-to-human
transmission is sustained. Recently, a novel H1N1 inﬂuenza
virus of combined swine, avian, and human origin became
pandemic within 2 months after its emergence in humans in
April 2009 (2,3). In terms of virulence, this virus is compa-
rable to the H2N2 virus that caused the relatively mild
pandemic of 1957 (4–7). However, a similar pandemic
scenario with a more virulent virus subtype like the highly
pathogenic avian inﬂuenza (HPAI) H5N1 virus would be
potentially catastrophic (8,9). With a lethality rate of approx-
imately 60% in reported laboratory-conﬁrmed human H5N1
cases (10), maximum preparedness is warranted in case
sustained human-to-human transmission were to evolve.
Vaccines and antivirals are critical assets in intervention
strategies against pandemic inﬂuenza (11,12). They represent
the only countermeasures that are clearly efﬁcacious in
preventing infection and treating illness (13)a n dt h e i r
availability plays a central role in pandemic preparedness
planning. Prophylactic use of antivirals could provide short-
term protection and may be helpful for early containment of
an emerging pandemic (14,15). However, the control of
infection in a pandemic will ultimately depend on protection
provided by vaccination.
For the H5N1 virus, effective pre-pandemic vaccines
have recently been developed, including whole inactivated
virus (WIV) vaccine and split-virus vaccine combined with
the oil-in-water emulsion adjuvants AS-03 or MF59 (16–19).
Because the eventual pandemic virus may be an antigenic
drift variant of the strain used to produce such pre-pandemic
vaccines, a complete match with the pandemic strain cannot
be guaranteed. However, the above vaccines have been
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to viruses of different H5N1 clades (16–18,20–23). Moreover,
even at suboptimal efﬁcacy, pre-pandemic vaccines may
reduce attack rates if deployed in an early stage of the
pandemic (24,25) or may serve as priming dose for the true
pandemic vaccine, thus saving time and resources (26).
Stockpiling of pre-pandemic H5N1 vaccines is therefore
considered an effective tool for containment and mitigation
of an emerging pandemic (15), and stockpiles have already
been established by multiple countries (27).
Current inactivated inﬂuenza vaccine formulations need to
be stored refrigerated because the major antigenic component,
the viral hemagglutinin (HA), is prone to degradation at higher
temperatures (28). However, cold-chain requirements may
seriously complicate the logistics of storage and deployment of
pre-pandemic and pandemic vaccines, with a risk of vaccines
escaping refrigeration. In general, cold-chain failure and ther-
mal instability is a major cause of vaccine loss in developing
countries (29), and has been linked to serious disease outbreaks
(30).Development oftemperature-stablevaccines for pandemic
use would promote worldwide usability by diminishing the
complexity of refrigerated storage and distribution logistics.
A well-known strategy to improve stability is conversion
of the liquid vaccine into dry powder (31). Biopharmaceut-
icals like inﬂuenza vaccines are preferably desiccated using
freeze-drying techniques (32). The vaccine is rapidly frozen
and water is, subsequently, extracted by sublimation under
reduced pressure. Detrimental stresses acting on the HA
antigenic components as a result of the freeze-dry process, as
well as degradation of the HA during subsequent storage, can
be counteracted by the use of cryoprotectants such as speciﬁc
sugars (33,34). Sugar is mixed with the liquid vaccine, and
during rapid freezing a glassy sugar matrix is formed in which
water and vaccine constituents are captured. The physical
barrier separating the vaccine constituents and molecular
immobility provided by the matrix prevent the vaccine from
degradation. Also, the matrix prevents further crystallization
of water molecules upon extended cooling. After drying, the
vaccine components are incorporated in a dry sugar glass, in
which the water has been spatially replaced by sugar and the
structural integrity of the vaccine constituents is preserved.
Here, we investigated the effect of ambient and high
storage temperatures over time on the immunogenicity of
inﬂuenza A/Vietnam/1203/2004 (H5N1) WIV vaccine. Vaccines
were either stored conventionally in buffer solution or as sugar-
stabilized dry-powder formulations and immunogenicity was
assessed in a mouse model. Inulin and trehalose sugars, which
have the intrinsic capacity to maintain a glassy state at high
temperatures (35,36), were used as stabilizing agents.
METHODS
Vaccine Preparation and Storage Conditions
H5N1 virus (NIBRG-14) was provided by the National
Institute for Biological Standards and Controls(NIBSC, Potters
Bar, UK), and is a 2:6 reassortant between A/Vietnam/1194/
2004 (H5N1) and A/PR/8/34 (H1N1) virus produced by reverse
genetics technology. WIV was obtained by virus propagation on
embryonated chicken eggs, and inactivation of the virus
preparation with 0.1% β-propiolactone. The hemagglutinin
protein concentration in the vaccines was determined by single
radial immunodiffusion (SRID) (37).
Freeze-drying of WIV was performed as described
previously (38). Brieﬂy, glass vials containing a mixture of
200 µl of a 16% w/v sugar (either trehalose or inulin) solution
in HBS (2 mM Hepes, 0.15 M NaCl, pH 7.4), or HBS without
sugar, and 200 µl WIV (66 µg HA) in HBS (approximated
sugar:HA ratio of 500:1 (w/w) were frozen in liquid nitrogen
for 10 min and subsequently lyophilized in a Christ Alpha 1-4
freeze-dryer (Salm en Kipp, Breukelen, The Netherlands).
The setting of the freeze-dryer was −35°C for the shelf
temperature, −55°C for the condenser temperature, and
0.220 mbar pressure. After 24 h, the pressure was reduced to
0.060 mbar and the shelf temperature was gradually raised to
20°C. This status was maintained for another 24 h. The dried
samples were either directly rehydrated for experiments or
stored in a silica gel containing desiccator at 20°C or 40°C. The
humidity in the desiccator was maintained at the level of 10±
2% RH. As shown by Hinrichs et al. at 10% RH, trehalose and
inulin glasses are equally hygroscopic (39). After, storage
vaccines were rehydrated shortly before immunization.
Hemagglutination of Erythrocytes
To determine the particle titer of the vaccines a standard
hemagglutination assay was used. Vaccines were serially
diluted twofold in PBS in duplicate, starting with a 10 times
dilution in the ﬁrst well of a microtiter plate, so that the end
volume per well was 50 µl. An equal volume of a 1%
suspension of fresh guinea pig erythrocytes in PBS was added
and the plates were incubated at room temperature for 2 h.
The titer was determined as the reciprocal of the highest
dilution that yielded complete hemagglutination.
Hemolysis of Erythrocytes
Thehemolysisassaywasperformedasdescribedpreviously
(40). In short, WIV vaccine (1 µg HA) in 50 µl HNE buffer
(5 mM Hepes, 0.15 M NaCl, 0.1 mM EDTA, pH 7.4) was added
to 4×10
7 human erythrocytes in800 µl HNE. Fifty microlitersof
fusion buffer (pH 5.5) was added to initiate viral membrane
fusion. The total mixture was incubated 0.5 h at 37°C, and
subsequently centrifuged at 350×g for 10 min. Absorbance of
thesupernatantwasredat540nm,representingthehemoglobin
liberated from the lysed erythrocytes. The absorbance was
corrected for autohemolysis in absence of WIV vaccine. The
amount of hemolysis was then given as a percentage of the
maximal hemolysis, which was determined by lysing
erythrocytes in water.
Immunization
For immunization experiments, 8–10-week-old female
Balb/c mice were purchased from Harlan Netherlands B.V.
(Zeist, The Netherlands). All experiments were conducted
with approval of the local Institutional Animal Care and Use
Committee. Mice were intramuscularly injected in both their
calf muscles with a total of 50 µl WIV vaccine (5 µg HA) in
HBS, equally divided over both injection sites. Mouse
numbers per immunization group were as follows: liquid
WIV; n=5–6, freeze-dried WIV with or without sugar; n=6–8,
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immunization, sera were collected for evaluation.
ELISA
ELISA assays were performed as described previously
(41). Brieﬂy, microtiter plates (Greiner, Alphen a/d Rijn, The
Netherlands) coated with 0.2 µg inﬂuenza H5N1 (NIBRG-14)
subunit vaccine per well were blocked with a 2% milk
solution. Two-fold serial dilutions of serum samples in
0.05%Tween 20/PBS (PBS/T) were added to the wells in
duplicate and incubated for 1.5 h. Bound H5N1-speciﬁc IgG,
IgG1 or IgG2a antibodies were detected with a horseradish
peroxidase-conjugated goat anti-mouse IgG-isotype antibody
(Southern Biotech, Birmingham, AL). All incubations were
performed at 37°C. The staining was performed with o-
phenylene-diamine (OPD) (Eastman Kodak Company) and
absorbance at 492 nm was measured by an ELISA reader
(Bio-tek Instruments, Inc.). The antibody titer was calculated
by extrapolating the serum dilution corresponding to an OD
of 0.2 using linear regression.
Hemagglutination Inhibition Assay
The hemagglutination inhibition (HI) assay was per-
formed as described previously (42). In short, 50 µl kaolin
absorbed, heat-inactivated mouse serum in PBS (1:4) was
serially diluted twofold in a microtiter plate in duplicate.
Next, 50 µl of four hemagglutination units (HAU) of H5N1
(NIBRG-14) virus in PBS was added and incubated for
40 min at RT. Finally, 50 µl of 1% guinea pig erythrocytes
(Harlan) in PBS was added to each well and HI titers were
determined after 2 h incubation at RT. HI titers are given as
the reciprocal of the highest serum dilution producing
complete inhibition of hemagglutination.
Statistical Analysis
Statistical analysis on antibody titers was performed using
the unpaired Student’s t test. p values of p<0.05 and p<0.01
were considered statistically signiﬁcant and highly signiﬁcant,
respectively.
RESULTS
Effect of Freeze-drying and Reconstitution on Vaccine
Immunogenicity
WIV vaccines were freeze-dried with or without sugar
and samples were stored, with WIV vaccine kept in suspen-
sion (liquid WIV). Immediately after drying, samples of each
vaccine were reconstituted in water and tested alongside
liquid WIV, to assess the effect of the actual freeze-drying
process on the vaccines, and to obtain reference values for the
storage experiments. Evaluation involved assessment of the
hemagglutination or hemolytic activities of the vaccines as a
measure for the structure and function of the viral particles.
Any effect of inulin or trehalose on the hemagglutination and
hemolysis assay was excluded, by testing a similar concen-
tration of the freeze-dried sugar without viral particles. The
results shown in Table I demonstrate that freeze-drying of
WIV with or without trehalose or inulin did not have adverse
effects on its hemagglutination or hemolytic activities. Pres-
ervation of these activities indicates that the sialic-acid-
binding capacity and the membrane fusion activity of the
HA proteins were retained.
To determine whether the preservation of in vitro
vaccine activity after freeze-drying was accompanied by
preservation of in vivo vaccine potency, mice were intra-
muscularly injected with vaccine doses of 5 μg HA. Four
weeks after immunization, the antibody responses induced by
the freeze-dried vaccines were compared to those induced by
liquid WIV. WIV freeze-dried without sugar (FD) induced
slightly lower IgG titers (p=0.001) than liquid WIV, while HI
titers were not signiﬁcantly diminished (p=0.08; Fig. 1a, b;
0 day). WIV freeze-dried with trehalose (FDT) was equally
immunogenic as liquid WIV, while WIV freeze-dried with
inulin (FDI) induced slightly lower IgG titers (p=0.02) but
similar HI titers. In conclusion, freeze-drying with or without
sugar did not affect the immunogenic potency of H5N1 WIV
vaccine substantially.
Effect of Storage at Ambient Temperature on Vaccine
Immunogenicity
The freeze-dried vaccines and liquid WIV were subse-
quently stored at 20°C. Three months and 1 year later, samples
were tested for their capacity to induce antibody responses in
mice. After 3 months of storage, no signiﬁcant differences in
serum IgG and HI titers induced by liquid WIV, FDT, or FDI
vaccines wereobserved compared to liquid WIV conventionally
stored at 4°C (Fig. 1a, b; 3 months). In contrast, FD vaccine
inducedsubstantiallylowermeanIgGandHItiterscomparedto
liquid WIV at 4°C (22.4-fold (p=0.03) and 3.5-fold (p=0.04),
respectively (Fig. 1a, b; 3 months). Consequently, FD vaccine
was excluded from further evaluation.
After 1 year of storage at 20°C, liquid WIVand both FDT
and FDI still induced considerable H5N1-speciﬁc antibody
responses. The mean IgG titer induced by liquid WIV stored
at 20°C was only slightly, but not signiﬁcantly (p=0.07), lower
than that induced by liquid WIV stored at 4°C (Fig. 1a, b;
1 year), and also the mean HI titer was not signiﬁcantly altered
(Fig. 1a, b; 1 year). IgG titers induced by FDI were moderately
lower (2.2-fold, p=0.005) with only a marginal decrease in HI
titers. FDT showed a more substantial decrease in both mean
IgG and HI titers (p=0.003andp=0.03, respectively).
Table I. Effect of High Storage Temperature on Hemagglutination
and Hemolysis Activity of the Vaccines
Vaccine
Hemagglutination titer
(10×
2 log) Hemolysis (% of max)
Temperature − 40°C – 40°C
Duration 0 Day 3 Months 0 Day 3 Months
Liquid 11 5 67.9 0
FD ≥12 7 90.6 4.3
FDT 11 8 81.5 35.3
FDI 11 8 83.3 15.1
Immunization groups: liquid liquid WIV, FD freeze-dried WIV without
sugar, FDT freeze-dried WIV with trehalose, FDI freeze-dried WIV
with inulin
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points may be subject to inter-assay variation, (pooled) sera
from all immunization experiments were tested in a single
assay, in order to compare the immunogenicity of the vaccines
over time (Fig. 2). Clearly, at 20°C, the effect of storage
duration on the immunogenic potency of the vaccine was
minimal for liquid WIVand FDT and FDI vaccine. IgG titers
dropped maximally by a factor of 1.9 (liquid WIV), and the
maximum effect on HI titers was a twofold reduction (FDT
and FDI), after 1 year of storage (Fig. 2a/b). More than
twofold reductions in IgG or HI titers were only seen for FD
vaccine after 3 months storage. In conclusion, liquid WIVand
sugar-stabilized freeze-dried WIV revealed only minor reduc-
tions in the immunogenicity after 1 year of storage at 20°C.
At this condition, substantial deterioration of immunogenicity
of WIV vaccine was seen only for WIV freeze-dried in
absence of sugar excipient.
Effect of High Storage Temperature on Vaccine Immunogenicity
To simulate more challenging conditions vaccines may
encounter during storage and transportation, the vaccines
were put on shelf at 40°C for 3 months. These conditions
negatively affected the hemagglutination and hemolysis
activity of all vaccines, but strongest for liquid WIV and FD
vaccine (Table I). Subsequent immunization of mice revealed
a strong decrease in IgG and HI titers induced by liquid WIV
stored at 40°C, compared to WIV freshly prepared from a
frozen virus stock (Fig. 3a, b). The immunogenic potency of
vaccines freeze-dried with sugars was much better preserved
under these challenging conditions. For FDT, vaccine a slight
decrease in mean IgG titer (1.4-fold, p=0.08) together with a
more substantial decrease in HI titer (2.3-fold, p=0.01) was
found. Responses to FDI vaccine were not signiﬁcantly
different from those to freshly prepared vaccine (Fig. 3a, b).
In contrast, freeze-drying without additional measures to
stabilize the vaccine resulted in strongly reduced IgG and HI
titers after storage at 40°C. Compared to liquid WIV stored at
40°C, both FDT and FDI stored at 40°C induced signiﬁcantly
higher IgG titers (p=0.002 and p=0.00001, respectively), and
HI titers (p=0.002 and p=0.02, respectively), which was not
the case for FD vaccine (Fig. 3a, b).
The effect of high storage temperature relative to
ambient storage temperature on vaccine immunogenicity is
summarized in Fig. 4. Serum pools of the different immuniza-
tion groups were run in a single assay, and the IgG and HI
titers were plotted including those induced by liquid WIV
stored at 4°C as a reference. The deteriorating effect of
Fig. 1. Antibody responses induced by liquid and freeze-dried WIV vaccines before and after storage at ambient
temperature. Serum H5N1-speciﬁc IgG titers were determined by ELISA and are given as geometric mean titers+standard
error of the means (SEM), before storage, and after 3 months and 1 year storage (a). The serum capacity to inhibit
agglutination of guinea pig erythrocytes by H5N1 vaccine virus is given in geometric mean HI titers+SEM, before storage,
and after 3 months and 1 year of storage (b). Immunization groups are plotted on the x axis with the vaccines’ actual storage
temperature in degrees Celsius: liquid liquid WIV, FD freeze-dried WIV without sugar, FDT freeze-dried WIV with
trehalose, FDI freeze-dried WIV with inulin. HI titers below the detection limit were assigned half the value of the lowest
detectable serum dilution, which was 8. *p<0.05, **p<0.01. nd not determined
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FD vaccine. In case of FD formulation, maximum deterio-
ration was already observed at moderate temperatures. If
stored as FDT or FDI formulation, however, vaccines
remained stable independent of the storage temperature.
Preservation of the Quality of the Immune Response to WIV
The ratio of IgG2a and IgG1 subtype antibodies induced
by the vaccine is important for protective efﬁcacy. Relatively
high IgG2a titers are representative of the Th1-type response
characteristically induced by whole virus particles (42,43) and
are associated with better protection against a challenge with
homologous virus in mice (44). We, therefore, evaluated the
effect of freeze-drying and storage of the vaccine on the
phenotype of the induced antibody response. When WIV was
stored in buffer solution, the IgG2a-dominated antibody
response was preserved at all storage temperatures and
storage durations tested (Table II). Freeze-drying in absence
of a stabilizing sugar excipient reduced the IgG2a/IgG1 ratio
to the level of a mixed IgG2a/IgG1 phenotype. Subsequent
storage of the FD vaccine further lowered the IgG2a/IgG1
ratio resulting in a shift to a IgG1-dominated antibody
response within 3 months, independent of the storage
temperature. In contrast, FDT and FDI vaccine induced an
IgG2a-dominated antibody response after storage independ-
ent of storage duration and temperature.
DISCUSSION
The immunogenicity of WIV vaccine depends on the
presence and integrity of the HA proteins and an intact viral
particle structure (42,45). The HA antigens provide the B-cell
epitopes and deﬁne the speciﬁcity of the antibody response,
while the viral particle acts as a vehicle for the vaccines
primary immunopotentiating agent, the viral single-stranded
RNA (ssRNA). Its immunopotentiating activity is exerted
through binding to Toll-like receptor 7 (TLR7) in the
endosomes of recipient host cells, and triggering of the innate
immune system (41,46,47). To a large extent, this mechanism
accounts for the superior immunogenicity of WIV compared
to split-virus formulations or subunit vaccines, which do not
contain intact viral RNA (41). TLR7 signaling also deter-
mines the response type, being characteristically of a Th1
Fig. 2. Effect of storage duration on the vaccines capacity to induce
antibody responses. Pooled sera of each group of mice immunized at
different time points with liquid or freeze-dried WIV vaccine were
tested simultaneously on H5N1-speciﬁc IgG or hemagglutination-
inhibiting capacity. Bars represent the average values of duplicate
determinations (deviations were less than 0.2). Immunization groups
are plotted and labeled as in Fig. 1. Storage duration: 0 day (white bars),
3m o n t h s( gray bars), 1 year (black bars). nd not determined
Fig. 3. Effect of high storage temperature on the immunogenic
potency of the vaccines. Vaccines were stored for 3 months at 40°C
and subsequently injected in mice. Serum H5N1-speciﬁc IgG titers (a)
and HI titers (b) were determined, and are shown as geometric mean
titers+SEM. Immunization groups are labeled as in Fig. 1. The group
immunized with liquid WIV, which had not been subjected to the
storage experiment, serves as a standard. *p<0.05 when compared
with the standard;
#p<0.05
##p<0.01 when compared with liquid WIV
stored at 40°C
219 Stable Dry-powder H5N1 Vaccinetype for WIV, with a high amount of IgG2a/c antibodies in
mice.
In liquid WIV vaccine, the antigenic properties of HA
and the immunopotentiating activity provided by the ssRNA
appear to be remarkably stable. Our results show that the
immunogenicity of WIV vaccine stored in buffer solution at
20°C remained well preserved with minimal loss of activity
over a period of at least 12 months. In contrast, seasonal
subunit vaccine (H3N2) stored in buffer solution at ambient
(25°C) temperature was reported to lose potency already
over a period of 12 to 20 weeks (28). Compared to subunit
vaccine, WIV, therefore, appears to be more stable. Yet, it
should be noted that the comparability of the two studies is
limited since they differ in the virus strains used for vaccine
production and the method by which vaccine stability was
assessed (in vivo immunogenicity versus SRID (31)). At high
storage temperature (40°C), the immunogenic potency of
liquid WIV rapidly deteriorated. Progressive degradation of
HA antigens and/or loss of intact viral particles, as reﬂected
in the strongly reduced hemagglutination and hemolytic
activity of the vaccine, may likely be the cause. Yet, the
antibody response remained Th1 skewed, which may indicate
that a small amount of viral particles escaped degradation, as
it was shown previously that even a very low dose of viral
particles is sufﬁcient for Th1 skewing of the response to WIV
vaccine (44).
At high storage temperature, dry-powder formulations were
superior to liquid WIV, as reported by others (29,48). With the
use of sugar stabilization no substantial loss of immunogenicity
was observed after storage of freeze-dried WIV for 3 months at
40°C. Furthermore, sugar stabilization played a critical role in
preserving the Th1-skewing capacityofthe vaccine duringfreeze-
drying and subsequent storage. Freeze-drying in absence of sugar
led to a mixed Th1/Th2 antibody response, which further shifted
during storage at elevated temperature to an overt Th2 type
response, while the characteristic Th1 phenotype of the WIV
response was retained when sugars were used during freeze-
drying. Sugar molecules obviously play a role in preserving
effective TLR7 signaling by the ssRNA, probably by stabilizing
the viral particle structure and protecting the viral ssRNA from
degradation. Sugars are known to stabilize enveloped viruses
during freeze-drying (49,50), and trehalose and inulin have the
capacity to stabilize lipid bilayers (35,36,51). In freeze-drying
experiments with ‘empty’ viral envelopes (virosomes), use of
inulin was found to preserve the vesicular structure, while
absence of sugar stabilization resulted in complete disintegration
after rehydration (38). The mode of action of trehalose and inulin
is presumably by replacement of the water molecules situated in
between the hydrophilic heads of the lipids. Hereby, a detrimen-
tal phase transition of the viral membrane upon rehydration is
prevented and the vaccine particles are preserved (35).
By assessing immunogenicity in vivo we discovered an
important role for sugar compounds in preserving not only
the quantity but also the quality of the immune response to
WIVafter freeze-drying and storage. Previous storage studies
that showed improved stability of freeze-dried WIV used the
hemagglutination assay to determine vaccine stability, which
provides a quantitative measure only (29,33). The shift from a
Th1 response to WIV before freeze-drying to a Th2 response
to WIV after freeze-drying in absence of sugar-stabilization
could not have been predicted from hemagglutination results,
Fig. 4. Effectofstoragetemperature onthevaccines’ capacity to induce
antibody responses. Pooled sera of each group of mice immunized with
liquid or freeze-dried WIV vaccine, which had been stored for 3 months
at different temperatures, were tested simultaneously on H5N1-speciﬁc
IgG or HI capacity. Bars represent the average values of duplicate
determinations (deviations were less than 0.2). Immunization groups as
in Fig. 1. Storage temperatures: 4°C (white bars), 20°C (gray bars), 40°C
(black bars)
Table II. Dominance of IgG Subtypes in the Antibody Response to
Vaccination. Immunization Groups are Labeled as in Table I
Vaccine 0 months 3 months 12 months
Liquid 4°C lgG2a
a lgG2a lgG2a
20°C nd lgG2a lgG2a
40°C nd lgG2a nd
FD 20°C lgG1/lgG2a
b lgG1 nd
40°C nd lgG1 nd
FDT 20°C lgG2a lgG2a lgG2a
40°C nd lgG2a nd
FDI 20°C lgG2a lgG2a lgG2a
40°C nd lgG2a nd
nd not done
aIgG2a or IgG1 were deﬁned dominant if the IgG2a/IgG1 ratio was
≥1.5 or ≤0.5, respectively
bFor ratios between 0.5 and 1.5, the response was deﬁned as mixed
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component, like the SRID. In vitro HA stability tests alone
are therefore insufﬁcient to obtain a complete representation
of WIV vaccine stability.
The efﬁcacy of inﬂuenza vaccines is determined by the
induction of an effective antibody response. The serum HI
titer, which is a measure for the magnitude of the antibody
response, is the principle correlate of protection used to
evaluate the efﬁcacy of current human seasonal and pre-
pandemic inﬂuenza vaccines. For seasonal vaccines an HI
titer of >40 is considered to be protective (52–55). For the
mouse model, no protective titer has been deﬁned. Due to the
intrinsic low immunogenicity of H5N1 virus and the single-
dose immunization scheme the maximal titer reached in our
experiments was 32. It has to be noted that immunogenicity in
terms of HI and IgG titers does not necessarily correlate with
protective efﬁcacy. In the mouse model, the relative amounts
of IgG1 and IgG2a (or IgG2c), expressed in the IgG2a/IgG1
ratio, appear to be decisive for protection (40,56,57). IgG2a-
dominated responses are clearly more effective than IgG1-
dominated responses. Yet, in the absence of signiﬁcant
differences in HI and IgG titers and similar IgG subtype
dominance, as observed, for example, for liquid WIV, FDI,
and FDT during storage at ambient temperatures, protective
efﬁcacy is likely to be comparable.
The preservability of WIV vaccine is strongly increased
by sugar stabilization and freeze-drying. Similarly, other
formulations like subunit, split-virus, and virosome (31)
vaccines have been successfully freeze-dried and stabilized
with sugars (summarized in (31)). Yet, a combination of
increased stability together with speciﬁc features of WIV
which promote vaccine availability, like strong immunogenic-
ity, dose sparing quality and manufacturing simplicity (46),
make dry-powder WIV an apt candidate formulation for pre-
pandemic stockpiling. Based on the results of storage at 40°C
it may also be predicted that dry-powder WIV will have a
shelf-life exceeding that of liquid WIV, when kept under
optimal refrigerated conditions (52,58). An extended vaccine
shelf-life could delay costly replacement of stocks when
vaccines reach their expiry date. In case of a pandemic
emergency, deployment of dry-powder vaccine stocks may be
exerted without refrigeration unless the temperatures are
extremely high. This could speed up pandemic intervention
and reduce losses due to cold-chain failures.
CONCLUSION
Thelackofsuitablevaccinesduringtheinitialemergenceof
the New Inﬂuenza A (H1N1)swl pandemic virus in 2009, and its
rapidly global spread underscores the importance of effective
pre-pandemic vaccine stockpiles. Although this virus was of an
unforeseen subtype, it remains important that stockpiles of
vaccines against identiﬁed potentially dangerous virus strains
like the H5N1 virus are prepared and kept in place. Our results
suggest that for stockpiling liquid H5N1 WIV vaccine refriger-
ation may not be an absolute requirement to preserve the
vaccines immunogenicity, as long as the temperature remains
below20°C.Furthermore,conversionfromliquidtodry-powder
formulation increases theversatility ofWIV vaccine byallowing
storageoutside thefridgeathigher temperatures,upto 40°Cfor
at least3 months. Because of its improved stability, useof sugar-
stabilized freeze-dried H5N1 WIV vaccine could increase the
efﬁcacy of pre-pandemic stockpiling and subsequent vaccine
deployment.
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